Public release date: 14-May-2012 [ | E-mail | Share ]

Contact: Sophie Mohin smohin@liebertpub.com Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 7, 2012The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology, a new peer-reviewed journal from Mary Ann Liebert, Inc. For a copy of the article "A Biohybrid Device for the Systemic Control of Acute Inflammation," please contact journalmarketing1@liebertpub.com.

"A device like this has the promise to be the 'Goldilocks' of inflammation to be that 'just right' modulation of inflammation," says Yoram Vodovotz, PhD, Department of Surgery, University of Pittsburgh.

This is the first report of a device in essence an auxiliary organ that can reprogram the inflammatory response at the whole-organism level. It represents a foundational concept and design that can accommodate cells genetically modified in an infinite variety of ways and that can be engineered and tailored to meet many different clinical applications.

###

About the Journal

Disruptive Science and Technology, a breakthrough, highly innovative, peer-reviewed journal spearheaded by Editor-in-Chief Alan J. Russell, PhD, Highmark Distinguished Professor, Carnegie Mellon University, cultivates, harnesses, and explores how existing paradigms can be changed to improve human health, well-being, and productivity. The Journal provides a multimedia platform and forum for ideas and opportunities, promotes breakthrough science and engineering, facilitates the innovator-market relationship, and accelerates the transition from bench to society. Bold, transparent, and resistant to limitations driven by protection of the science and engineering status quo, Disruptive Science and Technology provides the first destination for those seeking to publish game-changing results that have the capacity to alter the way we live. For complete journal details, please visit the Disruptive Science and Technology website at http://www.disruptivescience.com.

About the Publisher

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Human Gene Therapy and HGT Methods, and Rejuvenation Research. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc. website at http://www.liebertpub.com.

Original post:

Cutting-edge device controls acute inflammation